Innate Pharma (IPHA) Change in Working Capital (2019 - 2025)
Innate Pharma (IPHA) posted quarterly Change in Working Capital of -$2275.9 for Q4 2025, down 108.33% year-on-year from $27310.9 in Q4 2024, and down 108.33% on a QoQ basis from $27310.9 in Q4 2024.
Innate Pharma (IPHA) Change in Working Capital (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has reported Change in Working Capital for 7 consecutive years, with -$2275.9 the latest figure, recorded in Q4 2025.
- Quarterly Change in Working Capital fell 108.33% year-over-year to -$2275.9 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $48932.0 (up 714.29% YoY) and the FY2025 annual result came in at $12.1 million, up 127.15% from the prior year.
- Change in Working Capital declined to -$2275.9 in Q4 2025 per IPHA's latest filing, from $27310.9 in the prior quarter.
- Over the last five years, Change in Working Capital for IPHA reached as high as $27310.9 in Q4 2024 and fell as low as -$1.7 million in Q2 2021.
- A 5-year average of -$434048.3 and a median of -$2275.9 in 2025 frame the typical range for Change in Working Capital.
- Annual changes were most pronounced in 2021 — Change in Working Capital sank 366.54% — and 2024, when it surged 300.0%.
- Year by year, Change in Working Capital stood at -$1.3 million in 2021, then jumped by 101.27% to $17069.3 in 2022, then plunged by 60.0% to $6827.7 in 2023, then jumped by 300.0% to $27310.9 in 2024, then slumped by 108.33% to -$2275.9 in 2025.
- According to Business Quant data, Change in Working Capital over the past three periods registered -$2275.9, $27310.9, and $6827.7 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innate Pharma | 157.68 Mn | 157.68 Mn | - | -2,275.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,275.91 |
| Dec 31, 2025 | -2,275.91 |
| Dec 31, 2024 | 27,310.90 |
| Dec 31, 2024 | 27,310.90 |
| Dec 31, 2023 | 6,827.73 |
| Dec 31, 2023 | 6,827.73 |
| Dec 31, 2022 | 17,069.31 |
| Dec 31, 2022 | 17,069.31 |
| Jun 30, 2022 | -59,173.62 |
| Jun 30, 2022 | -59,173.62 |
| Dec 31, 2021 | -1.35 Mn |
| Dec 31, 2021 | -1.35 Mn |
| Jun 30, 2021 | -1.68 Mn |
| Jun 30, 2021 | -1.68 Mn |
| Dec 31, 2020 | -289,040.38 |
| Dec 31, 2020 | -289,040.38 |
| Jun 30, 2020 | -424,456.94 |
| Jun 30, 2020 | -424,456.94 |
| Dec 31, 2019 | 625,874.85 |
| Dec 31, 2019 | 625,874.85 |